Related references
Note: Only part of the references are listed.Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma Early Results of a Multicenter Randomized Controlled Trial: the RAMIE Trial
Yang Yang et al.
ANNALS OF SURGERY (2022)
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
Tom van den Ende et al.
CLINICAL CANCER RESEARCH (2021)
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)
Chengqiang Li et al.
EUROPEAN JOURNAL OF CANCER (2021)
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Alexander M. Menzies et al.
NATURE MEDICINE (2021)
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
Lan Mu et al.
THORACIC CANCER (2021)
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy
Xue Bai et al.
CLINICAL CANCER RESEARCH (2021)
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
Huiyan Luo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.
Zhen Wang
JOURNAL OF CLINICAL ONCOLOGY (2021)
The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study.
Lingdi Zhao et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
Ian Chau et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.
Jingpei Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Epigenetic therapy inhibits metastases by disrupting premetastatic niches
Zhihao Lu et al.
NATURE (2020)
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang et al.
LANCET ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
K. Kato et al.
ANNALS OF ONCOLOGY (2020)
Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010
Shiliang Liu et al.
EUROPEAN JOURNAL OF CANCER (2020)
The value of enhanced CT scanning for predicting lymph node metastasis along the right recurrent laryngeal nerve in esophageal squamous cell carcinoma
Bin Li et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
Seong Yong Park et al.
JOURNAL OF THORACIC DISEASE (2020)
Esophageal and Esophagogastric Junction Cancers, Version 2.2019
Jaffer A. Ajani et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Elisa A. Rozeman et al.
LANCET ONCOLOGY (2019)
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
Jing Huang et al.
CLINICAL CANCER RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
Hong Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Use of a positional therapy device significantly improves nocturnal gastroesophageal reflux symptoms
S. Allampati et al.
DISEASES OF THE ESOPHAGUS (2017)
Japanese Classification of Esophageal Cancer, 11th Edition: part II and III
ESOPHAGUS (2017)
Cancer of the Esophagus and Esophagogastric Junction-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
Thomas W. Rice et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy Esophagectomy Complications Consensus Group (ECCG)
Donald E. Low et al.
ANNALS OF SURGERY (2015)
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joel Shapiro et al.
LANCET ONCOLOGY (2015)
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Amylou C. Dueck et al.
JAMA ONCOLOGY (2015)
Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma
R. L. G. M. Blom et al.
DISEASES OF THE ESOPHAGUS (2014)
Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901
Christophe Mariette et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis
Katrin M. Sjoquist et al.
LANCET ONCOLOGY (2011)
Optimizing docetaxel chemotherapy in patients with cancer of the gastric and Gastroesophageal junction - Evolution of the Docetaxel, Cisplatin, and 5-fluorouracil regimen
Jaffer A. Ajani
CANCER (2008)
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation
LR Chirieac et al.
CANCER (2005)
Share Paper
